Answers are grounded in this paper and cite their sources.
In Brief Purpose: To evaluate the occurrence of retinal pigment epithelial atrophy in patients with age-related macular degeneration undergoing anti–vascular endothelial growth factor therapy. Methods: The study is a retrospective review. Eligible were patients with age-related macular degeneration and choroidal neovascular membranes treated with anti–vascular endothelial growth factor between October 2007 and February 2011; they were followed for >3 months, with fundus photographs and fluorescein angiography at baseline and with autofluorescence and near-infrared autofluorescence images at baseline and follow-up. Demographics, visual acuity, the type of choroidal neovascular membranes, the number of treatments performed, and the length of follow-up were recorded. Autofluorescence and near-infrared autofluorescence images were evaluated for the presence or absence of areas of reduced signal. A multilevel logistic regression model was used to investigate the factors that may be associated with “progression of atrophy” at follow-up, which was the primary outcome of this study. Results: Sixty-three patients (72 eyes) were followed for a median of 16 months (range, 3–36 months). Atrophy at baseline was observed in 47% (34/72) of eyes; progression of atrophy occurred in 62% (45/72) of eyes at the last visit. The number of anti–vascular endothelial growth factor injections received was statistically significantly associated with the progression of atrophy at follow-up (odds ratio, 1.35; 95% confidence interval, 1.05–1.73; P = 0.02). Conclusion: Atrophy was frequently observed in patients with age-related macular degeneration and choroidal neovascular membranes undergoing anti–vascular endothelial growth factor therapy. Retinal pigment epithelial atrophy was frequently observed in patients with choroidal neovascular membranes and age-related macular degeneration undergoing anti–vascular endothelial growth factor therapy. Progression of retinal pigment epithelial atrophy occurred commonly during the follow-up and was also associated with the number of anti–vascular endothelial growth factor injections received and the presence of preexisting atrophy.
No takes yet. Share an insight, caveat, or question.
Lois et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: